Share on LinkedInShare on LinkedIn

ARTICLE · 31 AUGUST 2011

Recent Developments In Area Of Patent Settlement Agreements At EU Level (July 2011)

Van Bael & Bellis
Van Bael & Bellis
Contributor
Van Bael & Bellis

Van Bael & Bellis

Van Bael & Bellis is a leading independent law firm headquartered in Brussels with offices in...

View firm profile
Explore more from Van Bael & Bellis

On 6 July 2011, the European Commission announced that it has closed its antitrust investigation into allegations by Spanish pharmaceutical company Almirall.

European UnionAntitrust/Competition Law

On 6 July 2011, the European Commission announced that it has closed its antitrust investigation into allegations by Spanish pharmaceutical company Almirall that the German pharmaceutical company Boehringer Ingelheim filed for unmeritous patents in the area of new treatments for lung diseases and, more specifically, new treatments of chronic obstructive pulmonary disease ("COPD").

Boehringer is the market leader in the treatment of COPD. In 2003, it filed patent applications for new treatments of COPD relating to three broad categories of active substances. The categorical substance-based applications were so broad that they included a new active substance that Almirall had discovered. Almirall protested that the applications were unmeritous and that, if granted, could block or considerably delay the entry of its own competing medicines.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from